Cut and run
Sometimes it’s the unexpected or quirky changes that stand out
While many observers have almost exclusively focused on protein degradation in the context of modern chemical proximity approaches, this isn’t the only possibility when using a bifunctional small molecule.
Indeed, I would argue some of the most creative ideas we are seeing coming out of late may well turn out to be unexpected standouts in future clinical trials.
Yet their goal is a very different one from what we’ve seen from the majority in the clinic.
In this latest example of the genre, we turn our attention to an area where drug hunters have struggled to find solutions for, despite the challenge being a commonplace issue for many oncologists in the clinic…
To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
